{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:57:03Z","timestamp":1791896223490,"version":"4.3.4"},"reference-count":39,"publisher":"Harborside Press, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of pleural mesothelioma (PM) over the past decade. This review summarizes the history of immunotherapy in PM, covering studies of single-agent immunotherapy, combination checkpoint blockade, the integration of ICIs into frontline therapeutic strategies, and ICI-VEGF combinations. Also discussed are the emerging role of biomarkers in guiding first-line therapy selection for patients with PM and novel therapeutic approaches. Dual checkpoint blockade targeting PD-1 and CTLA-4 demonstrated clinical efficacy in early-phase studies and led to the pivotal phase III CheckMate 743 trial, which established nivolumab and ipilimumab as a standard first-line systemic therapy for PM, particularly in patients with nonepithelioid histology. Since that time, other combination therapy approaches have been explored. For example, chemoimmunotherapy studies have evaluated ICIs, including pembrolizumab and durvalumab, in combination with platinum chemotherapy, with pembrolizumab plus platinum-doublet chemotherapy expanding the approved frontline treatment options for PM. VEGF inhibition, validated in the phase III MAPS study, provided a biologic rationale for combining antiangiogenic agents with ICIs. This prompted investigation of bevacizumab in combination with atezolizumab and chemotherapy in the BEAT-meso study. Unfortunately, this combination did not provide meaningful benefit in this setting. Optimal patient selection and treatment sequencing remain undefined. Although robust data support the use of second-line immunotherapy after first-line chemotherapy, there is a paucity of evidence regarding the efficacy of chemotherapy following frontline ICI. Despite advancements in therapeutic options in PM, biomarker-driven treatment selection remains limited at this time. Future large clinical studies must incorporate validated and standardized biomarker subanalyses, including approaches such as circulating tumor DNA and multiomics, for biomarkers to become clinically relevant in this heterogeneous malignancy. Finally, novel therapeutic strategies, including bispecific antibodies, targeted therapies, perioperative immunotherapy, vaccines, and cellular therapies, are under active investigation and may further expand treatment options for patients with PM.<\/jats:p>","DOI":"10.6004\/jnccn.2026.7070","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:53:43Z","timestamp":1790697223000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy for Pleural Mesothelioma"],"prefix":"10.6004","volume":"24","author":[{"given":"Logan N.","family":"Roof","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Thorac Surg Clin","first-page":"367","article-title":"Pathology of malignant pleural mesothelioma","volume":"30","author":"Hung YP","year":"2020","unstructured":"Hung YP, Chirieac LR. Pathology of malignant pleural mesothelioma. Thorac Surg Clin 2020;30:367\u2013382."},{"key":"B2","series-title":"J Clin Oncol","first-page":"2081","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao AS","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081\u20132090."},{"key":"B3","series-title":"Cancer Med","first-page":"12208","article-title":"Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database","volume":"12","author":"Bou-Samra P","year":"2023","unstructured":"Bou-Samra P, Chang A, Azari F,  Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database. Cancer Med 2023;12:12208\u201312220."},{"key":"B4","series-title":"JTO Clin Res Rep","first-page":"100804","article-title":"Trends in mesothelioma mortality in the United States between 1999 and 2020","volume":"6","author":"Didier AJ","year":"2025","unstructured":"Didier AJ, Li M, Gheeya J,  Trends in mesothelioma mortality in the United States between 1999 and 2020. JTO Clin Res Rep 2025;6:100804."},{"key":"B5","series-title":"Lancet Oncol","first-page":"623","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley EW","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A,  Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017;18:623\u2013630."},{"key":"B6","series-title":"J Thorac Oncol","first-page":"1569","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen J","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF,  Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol 2018;13:1569\u20131576."},{"key":"B7","series-title":"Clin Cancer Res","first-page":"5485","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada M","year":"2019","unstructured":"Okada M, Kijima T, Aoe K,  Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 2019;25:5485\u20135492."},{"key":"B8","series-title":"Lancet Respir Med","first-page":"613","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap TA","year":"2021","unstructured":"Yap TA, Nakagawa K, Fujimoto N,  Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 2021;9:613\u2013621."},{"key":"B9","series-title":"Lancet Oncol","first-page":"1530","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell DA","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C,  Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530\u20131540."},{"key":"B10","series-title":"Ann Oncol","first-page":"1734","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: ETOP 9-15 PROMISE-meso trial","volume":"31","author":"Popat S","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U,  A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: ETOP 9-15 PROMISE-meso trial. Ann Oncol 2020;31:1734\u20131745."},{"key":"B11","series-title":"Cancer Discov","first-page":"1548","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak J","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA,  Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 2018;8:1548\u20131565."},{"key":"B12","series-title":"Transl Lung Cancer Res","first-page":"639","article-title":"Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma","volume":"9","author":"Brockwell NK","year":"2020","unstructured":"Brockwell NK, Alamgeer M, Kumar B,  Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. Transl Lung Cancer Res 2020;9:639\u2013645."},{"key":"B13","series-title":"Lancet Oncol","first-page":"239","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel A","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L,  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019;20:239\u2013253."},{"key":"B14","series-title":"Lancet","first-page":"375","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK,  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375\u2013386."},{"key":"B15","series-title":"Lancet","first-page":"2295","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu Q","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L,  Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma: a phase 3, open-label, randomised controlled trial. Lancet 2023;402:2295\u20132306."},{"key":"B16","series-title":"Lancet Oncol","first-page":"1213","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak AK","year":"2020","unstructured":"Nowak AK, Lesterhuis WJ, Kok PS,  Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol 2020;21:1213\u20131223."},{"key":"B17","series-title":"BMJ Open","first-page":"e057663","article-title":"Protocol of DREAM3R: durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma\u2013a phase 3 randomised trial","volume":"12","author":"Kok PS","year":"2022","unstructured":"Kok PS, Forde PM, Hughes B,  Protocol of DREAM3R: durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma\u2013a phase 3 randomised trial. BMJ Open 2022;12:e057663."},{"key":"B18","series-title":"Ann Oncol","article-title":"Primary results of DREAM3R: durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma: a phase 3 randomised trial","volume":"36","author":"Nowak AK","year":"2025","unstructured":"Nowak AK, Forde PM, Brown C,  Primary results of DREAM3R: durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma: a phase 3 randomised trial. Ann Oncol 2025;36(Suppl 2):S1646. Abstract LBA104."},{"key":"B19","series-title":"Eur Respir J","first-page":"1086","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans JPJJ","year":"2006","unstructured":"Hegmans JPJJ, Hemmes A, Hammad H,  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006;27:1086\u20131095."},{"key":"B20","series-title":"Lancet","first-page":"1405","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the MAPS trial: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman G","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J,  Bevacizumab for newly diagnosed pleural mesothelioma in the MAPS trial: a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405\u20131414."},{"key":"B21","series-title":"Ann Oncol","first-page":"548","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma (BEAT-meso)","volume":"36","author":"Felip E","year":"2025","unstructured":"Felip E, Popat S, Dafni U,  A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma (BEAT-meso). Ann Oncol 2025;36:548\u2013560."},{"key":"B22","series-title":"Ann Oncol","first-page":"129","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Popat S","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C,  Malignant pleural mesothelioma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:129\u2013142."},{"key":"B23","series-title":"Cancer Med","first-page":"1042","article-title":"Impact of mesothelioma histologic subtype on outcomes in malignant pleural mesothelioma","volume":"4","author":"Meyerhoff RR","year":"2015","unstructured":"Meyerhoff RR, Yang CFJ, Speicher PJ,  Impact of mesothelioma histologic subtype on outcomes in malignant pleural mesothelioma. Cancer Med 2015;4:1042\u20131052."},{"key":"B24","series-title":"Oncogene","first-page":"593","article-title":"BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities","volume":"45","author":"van Genugten JHLT","year":"2026","unstructured":"van Genugten JHLT, Fennell DA, Baas P. BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities. Oncogene 2026;45:593\u2013602."},{"key":"B25","series-title":"Nat Genet","first-page":"407","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno R","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD,  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 2016;48:407\u2013416."},{"key":"B26","series-title":"Cancer Res","first-page":"264","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo G","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C,  Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015;75:264\u2013269."},{"key":"B27","series-title":"Nat Commun","first-page":"5606","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han G","year":"2021","unstructured":"Han G, Yang G, Hao D,  9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 2021;12:5606."},{"key":"B28","series-title":"Science","first-page":"1214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov GV","year":"2016","unstructured":"Kryukov GV, Wilson FH, Ruth JR,  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 2016;351:1214\u20131218."},{"key":"B29","series-title":"J Thorac Oncol","first-page":"921","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw A","year":"2022","unstructured":"Louw A, Panou V, Szejniuk WM,  BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study. J Thorac Oncol 2022;17:921\u2013930."},{"key":"B30","series-title":"Cancers (Basel)","first-page":"3468","article-title":"The Hippo pathway effectors YAP\/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment","volume":"15","author":"Mokhtari RB","year":"2023","unstructured":"Mokhtari RB, Ashayeri N, Baghaie L,  The Hippo pathway effectors YAP\/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment. Cancers (Basel) 2023;15:3468."},{"key":"B31","series-title":"Cancer Res","first-page":"1349","article-title":"Personalized circulating tumor DNA profiling in malignant pleural mesothelioma","volume":"79","author":"Martinson LJ","year":"2019","unstructured":"Martinson LJ, Sharkey AJ, Dawson AG,  Personalized circulating tumor DNA profiling in malignant pleural mesothelioma. Cancer Res 2019;79:1349\u20131349."},{"key":"B32","series-title":"JTO Clin Res Rep","first-page":"100692","article-title":"Individualized cell-free DNA monitoring with chromosomal junctions for mesothelioma","volume":"5","author":"Parikh K","year":"2024","unstructured":"Parikh K, Harris FR, Karagouga G,  Individualized cell-free DNA monitoring with chromosomal junctions for mesothelioma. JTO Clin Res Rep 2024;5:100692."},{"key":"B33","series-title":"Nat Med","first-page":"4097","article-title":"Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses","volume":"31","author":"Reuss JE","year":"2025","unstructured":"Reuss JE, Lee PK, Mehran RJ,  Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses. Nat Med 2025;31:4097\u20134108."},{"key":"B34","article-title":"NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural","author":"Riely GJ","unstructured":"Riely GJ, Wood DE, Stevenson J,  NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 1.2026. Accessed June 5, 2026. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B35","series-title":"J Clin Oncol","first-page":"742","article-title":"Five-year clinical outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for unresectable pleural mesothelioma in CheckMate 743","volume":"44","author":"Scherpereel A","year":"2026","unstructured":"Scherpereel A, Baas P, Nowak AK,  Five-year clinical outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for unresectable pleural mesothelioma in CheckMate 743. J Clin Oncol 2026;44:742\u2013749."},{"key":"B36","series-title":"Lancet Respir Med","first-page":"457","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim E","year":"2024","unstructured":"Lim E, Waller D, Lau K,  Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med 2024;12:457\u2013466."},{"key":"B37","series-title":"Cancer Discov","first-page":"2748","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli PS","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I,  A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab. Cancer Discov 2021;11:2748\u20132763."},{"key":"B38","series-title":"J Transl Med","first-page":"232","article-title":"NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma","volume":"19","author":"Haakensen VD","year":"2021","unstructured":"Haakensen VD, Nowak AK, Ellingsen EB,  NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med 2021;19:232."},{"key":"B39","series-title":"PLoS One","first-page":"e0307204","article-title":"Integration of the PD-L1 inhibitor atezolizumab and WT1\/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma: protocol of the Immuno-MESODEC study","volume":"19","author":"Van den Bossche J","year":"2024","unstructured":"Van den Bossche J, De Laere M, Deschepper K,  Integration of the PD-L1 inhibitor atezolizumab and WT1\/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma: protocol of the Immuno-MESODEC study. PLoS One 2024;19:e0307204."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/10\/article-e267070.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/10\/article-e267070.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/10\/article-e267070.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:40:42Z","timestamp":1791895242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/10\/article-e267070.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7070","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}